<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Perotti, Michela</dc:creator>
  <dc:creator>Perez, Laurent</dc:creator>
  <dc:date>2019-12-28</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Human cytomegalovirus (HCMV) infects more than 70% of the human population worldwide. HCMV is responsible  for high morbidity and mortality in immunocompromised patients and remains the leading viral cause of congenital  birth defects. Despite considerable efforts in vaccine and therapeutic development, HCMV infection still represents  an unmet clinical need and a life-threatening disease in immunocompromised individuals and newborns. Immune  repertoire interrogation of HCMV seropositive patients allowed the identification of several potential antigens for  vaccine design. However, recent HCMV vaccine clinical trials did not lead to a satisfactory outcome in term of  efficacy. Therefore, combining antigens with orthogonal technologies to further increase the induction of  neutralizing antibodies could improve the likelihood of a vaccine to reach protective efficacy in humans. Indeed,  presentation of multiple copies of an antigen in a repetitive array is known to drive a more robust humoral immune  response than its soluble counterpart. Virus-like particles (VLPs) and nanoparticles (NPs) are powerful platforms  for multivalent antigen presentation. Several self-assembling proteins have been successfully used as scaffolds to  present complex glycoprotein antigens on their surface. In this review, we describe some key aspects of the  immune response to HCMV and discuss the scaffolds that were successfully used to increase vaccine efficacy  against viruses with unmet medical need.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://susi.usi.ch/global/documents/318908</dc:identifier>
  <dc:identifier>https://n2t.net/ark:/12658/srd1318908</dc:identifier>
  <dc:identifier>https://susi.usi.ch/documents/318908/files/Perotti_viruses_2019.pdf</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.3390/v12010035</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/ark/12658/srd1318908</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>CC BY</dc:rights>
  <dc:source>Viruses. - 2020, vol. 12, no. 1, p. 17 p</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">HCMV</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Cytomegalovirus</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">VLP</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Nanoparticle</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">Vaccine</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">Immune response</dc:subject>
  <dc:subject>info:eu-repo/classification/udc/61</dc:subject>
  <dc:title xmlns:ns7="xml" ns7:lang="en">Virus-like particles and nanoparticles for vaccine development against HCMV</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>